For the quarter ended September 2024, Novartis (NVS) reported revenue of $12.82 billion, up 8.8% over the same period last year. EPS came in at $2.06, compared to $1.74 in the year-ago quarter.The reported revenue represents a surprise of +1.63% over the Zacks Consensus Estimate of $12.62 billion. With the consensus EPS estimate being $1.94, the EPS surprise was +6.19%.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expe ...

Ad hoc announcement pursuant to Art. 53 LR Q3 net sales grew +10% (cc1, +9% USD) with core operating income up +20% (cc, +17% USD) Sales growth driven by continued strong performance from Entresto (+26% cc), Cosentyx (+28% cc), Kisqali (+43% cc), Kesimpta (+28% cc), Pluvicto (+50% cc) and Leqvio (+119% cc)Core operating income margin 40.1%, +340 basis points (cc), mainly driven by higher net sales Q3 operating income grew +123% (cc, +106% USD); net income up +121% (cc, +111% USD)Q3 core EPS grew +20% (cc, ...

This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace. If you like what you read here and would like to subscribe to, I'm currently offering a two-week free trial period for subscribers to take advantage of. My service offers a deep-dive analysis of many pharmaceutical companies. The Biotech Analysis Central SA marketplace is $49 per month, but for those who sign up for the yearly plan will be able to take advantage of a 33. ...

Novartis Renal Portfolio Investor Event Virtual, October 28, 2024 ს NOVARTIS Reimagining Medicine Disclaimer This presentation contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as "potential," "can," "will," "plan," "may," "could," "would," "expect," "anticipate," "seek," "look forward," "believe," "committed," "investigational," "pipeline," "launch," or similar te ...

Group 1 - The conference call is focused on Novartis AG's renal portfolio, highlighting its strategic importance and ongoing developments in this area [2][4] - Participants in the call include key executives from Novartis, such as the Head of Investor Relations and the President of Global Drug Development [1][2] - The call is being recorded and will be available for later access on the company's website, indicating a commitment to transparency and investor communication [2] Group 2 - The presentation will include forward-looking statements that may involve risks and uncertainties, which could lead to actual results differing from expectations [3] - The company emphasizes the importance of reviewing its Form 20-F and recent quarterly results for a comprehensive understanding of potential risks [3]

Investors interested in stocks from the Large Cap Pharmaceuticals sector have probably already heard of Novartis (NVS) and Eli Lilly (LLY) . But which of these two stocks is more attractive to value investors? We'll need to take a closer look to find out.The best way to find great value stocks is to pair a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system. The Zacks Rank favors stocks with strong earnings estimate revision trends, and our Style Scores highlight comp ...

I publish my best ideas and top coverage on the Growth Stock Forum . If you're interested in finding great growth stocks, with a focus on biotech, consider signing up. We focus on attractive risk/reward situations and track each of our portfolio and watchlist stocks closely. To receive e-mail notifications for my public articles and blogs, please click the follow button . And to go deeper, sign up for a free trial to Growth Stock Forum.Shares of Novartis (NYSE: NVS ) hit new all-time highs this summer and h ...

In its upcoming report, Novartis (NVS) is predicted by Wall Street analysts to post quarterly earnings of $1.94 per share, reflecting an increase of 11.5% compared to the same period last year. Revenues are forecasted to be $12.62 billion, representing a year-over-year increase of 7.1%.The current level reflects an upward revision of 0.2% in the consensus EPS estimate for the quarter over the past 30 days. This demonstrates how the analysts covering the stock have collectively reappraised their initial proj ...

If approved, patients in Europe with stage II or III HR+/HER2- early breast cancer (EBC) at high risk of recurrence, including those with node-negative disease, will be eligible for adjuvant treatment with Kisqali® (ribociclib) in combination with an aromatase inhibitor1 Recommendation is based on the Phase III NATALEE trial, where Kisqali added to endocrine therapy (ET) significantly reduced the risk of recurrence by 25% versus ET alone across a broad population of patients with HR+/HER2- early breast canc ...

Novartis (NVS) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of the most powerful forces impacting stock prices. The Zacks rating relies solely on a company's changing earnings picture. It tracks EPS estimates for the current and following years from the sell-side analysts covering the stock through a consensus measure -- the Zacks Consensus Estimate. Since a changing earnings picture ...